These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37811868)

  • 1. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
    Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
    Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The circadian rhythm key gene
    Wu G; Ren H; Hu Q; Ma H; Chen H; Zhou L; Xu K; Ding L
    Front Immunol; 2023; 14():1115809. PubMed ID: 37275880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal sequence receptor subunit 3: A novel indicator of immunosuppressive tumor microenvironment and clinical benefits from immunotherapy.
    Hu Q; Wu G; Ma H; Zhang J; Yang Z
    Cell Signal; 2023 Nov; 111():110871. PubMed ID: 37652395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK16 as a potential prognostic biomarker correlated with an immunosuppressive tumor microenvironment and benefits in enhancing the effectiveness of immunotherapy in human cancers.
    Qi J; Wu G; He M; Xu Y; Yang Z; Ding L; Wang Y; Zhang Z
    Aging (Albany NY); 2024 Jan; 16(2):1879-1896. PubMed ID: 38261737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
    Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
    Front Immunol; 2021; 12():812713. PubMed ID: 35069601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic pan-cancer analysis identifies cuproptosis-related gene DLAT as an immunological and prognostic biomarker.
    Xu L; Wu P; Rong A; Li K; Xiao X; Zhang Y; Wu H
    Aging (Albany NY); 2023 May; 15(10):4269-4287. PubMed ID: 37199628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of HGH1 in breast cancer prognosis: a study on immune response and cell cycle.
    Li H; Xu Y; Xu R; Du W
    BMC Cancer; 2024 Sep; 24(1):1122. PubMed ID: 39251967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
    Mo Z; Li P; Cao Z; Zhang S
    Front Immunol; 2021; 12():564948. PubMed ID: 34290693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RREB1 could act as an immunological and prognostic biomarker: From comprehensive analysis to osteosarcoma validation.
    Zhang Z; Liu B; Mei L; Chen R; Zhou H; Li Z
    Int Immunopharmacol; 2024 Dec; 143(Pt 1):113312. PubMed ID: 39405927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
    Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
    Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pan-cancer analysis identifies migrasome-related genes as a potential immunotherapeutic target: A bulk omics research and single cell sequencing validation.
    Qin Y; Yang J; Liang C; Liu J; Deng Z; Yan B; Fu Y; Luo Y; Li X; Wei X; Li W
    Front Immunol; 2022; 13():994828. PubMed ID: 36405728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors.
    Zhu M; Wang X; Zhang Q; Xie C; Wang T; Shen K; Zhang L; Zhou X
    Aging (Albany NY); 2024 Feb; 16(3):2563-2590. PubMed ID: 38315450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
    Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive pan-cancer analysis of role of GPRASP1, associated with clinical outcomes, immune microenvironment, and immunotherapeutic efficiency in pancreatic cancer.
    Du J; Chen Y; Liu G; Zeng Q; Zhou N; Du D
    Pathol Res Pract; 2023 Mar; 243():154374. PubMed ID: 36801507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-cancer analysis of AIM2 inflammasomes with potential implications for immunotherapy in human cancer: A bulk omics research and single cell sequencing validation.
    Qin Y; Pan L; Qin T; Ruan H; Zhang Y; Zhang Y; Li J; Yang J; Li W
    Front Immunol; 2022; 13():998266. PubMed ID: 36248785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.